Clinical Trials: Clinical Trials in China

Evolution of Clinical Trials in China: From GCP 2003 to NMPA Reforms

Posted on digi By digi

Sponsors conducting trials in China should prioritize early engagement with the NMPA through pre-submission consultations, ensure their protocols are adaptable to local hospital infrastructure, and partner with experienced CROs. Inspection readiness, training of investigators, and proactive CAPA systems are crucial for avoiding regulatory setbacks. Adopting harmonized SOPs across global and Chinese sites ensures consistency and reduces delays.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

NMPA Regulatory Framework for Multinational Clinical Trials

Posted on digi By digi

For successful MRCT execution in China, sponsors should adopt the following measures:
✔️ Engage early with the NMPA and CDE during protocol design.
✔️ Ensure sufficient Chinese patient representation in trial cohorts.
✔️ Partner with experienced local CROs familiar with site capacity and patient recruitment.
✔️ Maintain harmonized SOPs across global and Chinese sites.
✔️ Prepare for NMPA inspections with rigorous documentation and CAPA systems in place.
These practices reduce regulatory risk and improve trial execution efficiency.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Patient Recruitment Challenges in Chinese Clinical Trials

Posted on digi By digi

Sponsors can improve recruitment outcomes by engaging with local patient advocacy groups, deploying culturally tailored educational materials, and ensuring ethics committee approval of recruitment campaigns in advance. Partnering with Tier-2 hospitals under the mentorship of Tier-1 sites can expand access to patient populations while strengthening local research capacity. Early feasibility assessments are critical to setting realistic recruitment targets and timelines.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Role of Tier-1 vs Tier-2 Hospitals in Clinical Research in China

Posted on digi By digi

Sponsors should adopt a mixed-site strategy that leverages the strengths of Tier-1 hospitals while investing in the capacity building of Tier-2 hospitals. This includes providing GCP training, ensuring CRO support, and implementing phased mentorship programs. Feasibility assessments should evaluate infrastructure, staffing, and ethics oversight at both tiers to avoid recruitment bottlenecks and compliance risks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

How China’s HGRAC Affects Global Rare Disease Trials

Posted on digi By digi

Sponsors should begin HGRAC application preparation at the earliest stages of protocol development. Establishing partnerships with accredited Chinese research institutions can reduce approval risks. Sponsors should also design trial data management systems that comply with localization laws, and ensure transparency with patients and ethics committees regarding data handling. Regular communication with regulators helps mitigate delays.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Clinical Trial Data Transparency in China: Where It Stands

Posted on digi By digi

Sponsors can strengthen compliance by aligning Chinese registry practices with global standards, publishing results within 12 months, and ensuring multilingual trial summaries for patients. Establishing dedicated data management teams to monitor registry updates and implementing SOPs for transparency can mitigate risks. Collaborating with CROs experienced in registry compliance is also recommended.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

CRO Industry Growth in China: Opportunities and Challenges

Posted on digi By digi

Sponsors should select CRO partners based on demonstrated compliance history, quality management systems, and capacity to manage complex multinational trials. Conducting audits before contract award, providing training support, and establishing clear KPIs for monitoring and data integrity are essential. Building long-term partnerships with CROs enhances accountability and reduces trial risks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Oncology Clinical Trials in China: Current Trends

Posted on digi By digi

Sponsors should plan for competitive recruitment landscapes in Tier-1 hospitals by including Tier-2 sites in their strategies. Early engagement with the NMPA through Breakthrough or Conditional Approval pathways can accelerate timelines. Establishing strong pharmacovigilance systems and integrating RWE into protocols can enhance regulatory success and patient access.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Role of China in Global Vaccine Clinical Trials

Posted on digi By digi

Sponsors should adopt best practices such as engaging early with the NMPA, preparing robust pharmacovigilance systems, and designing culturally appropriate informed consent processes. Including Tier-2 hospitals in vaccine trials expands access to diverse populations. Collaboration with CROs and public health authorities ensures smooth operations and compliance.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Clinical Trial Site Accreditation in China Explained

Posted on digi By digi

Sponsors should conduct thorough site qualification visits, verify accreditation status, and establish SOPs for site monitoring. Early collaboration with CROs and local hospitals can mitigate risks. Building mentorship programs between Tier-1 and Tier-2 hospitals supports capacity building and ensures wider trial readiness across China.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials